Last reviewed · How we verify

Prevention of Transplant Rejection — Treatment Landscape & Competitive Intelligence

Prevention of Transplant Rejection (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Prevention of Transplant Rejection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Prograf TACROLIMUS Astellas Pharma Calcineurin Inhibitor Immunosuppressant Interferon gamma 1994-01-01
Deltasone prednisone Generic (originally Schering) Corticosteroid [EPC] Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor 1955-01-01
prednison prednison Wen Zhang Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Astellas Pharma · 1 drug in Prevention of Transplant Rejection
  2. Generic (originally Schering) · 1 drug in Prevention of Transplant Rejection
  3. Wen Zhang · 1 drug in Prevention of Transplant Rejection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Prevention of Transplant Rejection:

Cite this brief

Drug Landscape (2026). Prevention of Transplant Rejection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-transplant-rejection. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing